Alpine Immune Sciences Presents Initial Clinical Data On Povetacicept In Autoimmune Glomerulonephritis In A Late-Breaking Poster Session At The American Society Of Nephrology Kidney Week 2023
Portfolio Pulse from Benzinga Newsdesk
Alpine Immune Sciences has presented initial clinical data on Povetacicept in autoimmune glomerulonephritis at the American Society of Nephrology Kidney Week 2023. The low-dose Povetacicept was well tolerated and reduced UPCR by over 50% in IgA nephropathy. The company is now planning to begin a pivotal phase 3 IgAN study in the second half of 2024.
November 02, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alpine Immune Sciences' positive initial clinical data on Povetacicept and plans for a phase 3 study could potentially boost investor confidence and the company's stock price.
The positive initial clinical data on Povetacicept indicates that the drug is effective and well-tolerated, which is a positive sign for its future development and potential approval. The announcement of a planned phase 3 study also shows that the company is making progress in its drug development pipeline, which could attract more investors and potentially increase the stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100